jamunjar-logo
whatsapp
cartmembermenu
Search for
"test & packages"
"physiotherapy"
"heart"
"lungs"
"diabetes"
"kidney"
"liver"
"cancer"
"thyroid"
"bones"
"fever"
"vitamin"
"iron"
"HTN"

Advanced Queen (Female) Full Body

Full Body

102 parameters

image

Report in 24Hrs

image

At Home

fastingrequire

Fasting Required

Details

Advanced Health covering Blood, Diabetes, Heart, Liver, Kidney, Thyroid, Iron, Sugar, Inflamation, Bone, Vitamins, Urine, Cancer Marker, Pancreas, Cardiac Marker, Arthritis

₹5,527₹8,999

39% OFF

Parameters

  • List of Tests
    • Sugar (Glucose) Fasting
    • CBC - Complete Hemogram
    • Liver Function Test
      • Albumin
      • Alkaline Phosphatase
      • Bilirubin - Direct
      • Bilirubin - Indirect
      • Bilirubin - Total
      • AST/SGOT
      • ALT/SGPT
      • Total Protein
      • A/G Ratio
      • Gamma GT
      • Globulin
    • Kidney Profile
      • BUN
      • Calcium
      • Creatinine
      • Uric Acid
      • eGFR
      • BUN/Creatinine
      • Urea
      • Sodium
      • Potassium
      • Chloride
    • Lipid Profile
      • Cholestrol/HDL
      • LDL/HDL
      • Non HDL
      • VLDL
      • Total Cholestrol
      • Triglycerides
      • HDL
      • LDL
    • Iron Studies
      • Iron
      • TIBC
      • Transferrin Saturation
    • Thyroid Profile
      • Total T3
      • Total T4
      • TSH
    • Hba1c
    • eAG
    • ESR
    • hs-CRP
    • Vitamin B12
    • 25 OH Vitamin D
    • Urine Complete
    • RF
    • Phosphorous
    • Amylase
    • Lipase
    • Total IgE
    • Carcino Embryonic Antigen (CEA)
    • CA125
    • CA15.3

Super Advanced Wellness Package - Queen

  • Why is it done?
    • Comprehensive health screening: This premium wellness package provides an in-depth assessment of overall health status across multiple organ systems and metabolic functions
    • Early disease detection: Identifies subclinical or early-stage conditions including diabetes, cardiovascular disease, liver disease, kidney disease, anemia, thyroid disorders, and malignancies before symptoms develop
    • Cancer screening: Includes tumor markers (CEA, CA125, CA15.3) for surveillance of common malignancies in women, particularly breast, ovarian, and gastrointestinal cancers
    • Metabolic and endocrine assessment: Evaluates glucose metabolism, thyroid function, and metabolic markers through fasting glucose, HbA1c, TSH, and lipid profiles
    • Organ function monitoring: Assesses liver, kidney, and pancreatic function through comprehensive panels including LFTs, renal profile, amylase, and lipase
    • Hematological evaluation: Complete blood count assesses hemoglobin, red blood cells, white blood cells, and platelets to detect anemia, infection, or hematologic malignancies
    • Micronutrient and nutritional status: Evaluates iron stores, vitamin B12, and vitamin D levels to identify deficiencies affecting energy, cognition, and bone health
    • Inflammatory markers and immune function: Measures ESR, hs-CRP, total IgE, and RF to assess systemic inflammation and autoimmune conditions
    • Baseline and preventive health: Establishes baseline values for ongoing health monitoring and risk stratification for chronic disease prevention
    • Ideal for: Annual comprehensive wellness exams, pre-operative clearance, monitoring chronic conditions, assessing response to treatment, and women over age 40 seeking detailed health profiling
  • Normal Range
    • Sugar (Glucose) Fasting: 70-100 mg/dL (3.9-5.6 mmol/L) - Normal fasting blood glucose indicating proper glucose homeostasis
    • CBC - Complete Hemogram (28 parameters) includes: Hemoglobin (12.0-16.0 g/dL for women), Hematocrit (36-46% for women), RBC (4.0-5.2 million/µL), WBC (4.5-11.0 thousand/µL), Platelets (150-400 thousand/µL), and differential counts within normal ranges
    • Liver Function Test (11 parameters): Total Bilirubin (0.1-1.2 mg/dL), Direct Bilirubin (0.0-0.3 mg/dL), Indirect Bilirubin (0.1-0.9 mg/dL), AST/SGOT (10-40 U/L), ALT/SGPT (7-35 U/L), Alkaline Phosphatase (30-120 U/L), Total Protein (6.0-8.3 g/dL), Albumin (3.5-5.0 g/dL), Globulin (2.0-3.5 g/dL), A/G Ratio (1.0-2.5), Gamma GT (0-55 U/L)
    • Kidney Profile (10 parameters): Creatinine (0.6-1.2 mg/dL), BUN (7-20 mg/dL), Urea (2.5-7.1 mmol/L), eGFR (>60 mL/min/1.73m²), BUN/Creatinine Ratio (10-20), Uric Acid (2.6-6.0 mg/dL), Calcium (8.5-10.2 mg/dL), Phosphorous (2.5-4.5 mg/dL), Sodium (136-145 mEq/L), Potassium (3.5-5.0 mEq/L), Chloride (98-107 mEq/L)
    • Lipid Profile (8 parameters): Total Cholesterol (<200 mg/dL is desirable), HDL (>50 mg/dL for women), LDL (<100 mg/dL is optimal), VLDL (5-40 mg/dL), Triglycerides (<150 mg/dL), Cholesterol/HDL Ratio (<5.0), LDL/HDL Ratio (<3.0), Non-HDL Cholesterol (<130 mg/dL)
    • Iron Studies (3 parameters): Iron (60-170 µg/dL for women), TIBC (250-425 µg/dL), Transferrin Saturation (20-50%)
    • Thyroid Profile (3 parameters): TSH (0.4-4.0 mIU/L), Total T3 (80-200 ng/dL), Total T4 (4.5-12 µg/dL)
    • HbA1c: <5.7% (<39 mmol/mol) - Normal glucose control, eAG: <100 mg/dL - Estimated average glucose corresponding to HbA1c
    • ESR (Erythrocyte Sedimentation Rate): 0-20 mm/hr for women - Measures systemic inflammation
    • hs-CRP (High-Sensitivity C-Reactive Protein): <3.0 mg/L - Low cardiovascular risk, indicates minimal inflammation
    • Vitamin B12: 200-900 pg/mL (148-663 pmol/L) - Normal cobalamin status supporting neurologic and hematologic function
    • 25-OH Vitamin D: 30-100 ng/mL (75-250 nmol/L) - Optimal vitamin D status for bone and immune health
    • Urine Complete (18 parameters): Appearance (Clear), Color (Pale yellow to dark yellow), pH (4.5-8.0), Specific Gravity (1.010-1.025), Protein (Negative/Trace), Glucose (Negative), Ketones (Negative), Blood (Negative), Bilirubin (Negative), Nitrites (Negative), Leukocyte Esterase (Negative), and normal microscopy (WBC <5/hpf, RBC <3/hpf, Crystals absent, Casts absent)
    • RF (Rheumatoid Factor): <14 IU/mL - Negative result indicates absence of rheumatoid arthritis
    • Phosphorous: 2.5-4.5 mg/dL (0.8-1.45 mmol/L) - Normal serum phosphate level supporting bone and cellular function
    • Amylase: 30-110 U/L - Normal pancreatic enzyme levels indicating healthy pancreatic function
    • Lipase: 0-60 U/L - Normal pancreatic lipase indicating normal pancreatic exocrine function
    • Total IgE: <100 IU/mL - Normal immunoglobulin E level indicating minimal allergic sensitization
    • CEA (Carcinoembryonic Antigen): <2.5 ng/mL (non-smoker), <5 ng/mL (smoker) - Negative or low levels indicate absence of gastrointestinal or other malignancies
    • CA125: <35 U/mL - Normal level consistent with absence of ovarian cancer or benign ovarian pathology
    • CA15.3: <25 U/mL - Normal level indicating no evidence of breast cancer or breast disease
  • Interpretation
    • Sugar (Glucose) Fasting: Values 100-125 mg/dL indicate impaired fasting glucose (prediabetes); ≥126 mg/dL on repeat testing suggests diabetes mellitus; <70 mg/dL indicates hypoglycemia requiring evaluation for causes such as medication effects or insulinomas
    • CBC - Low hemoglobin (<12 g/dL) suggests anemia from iron deficiency, B12/folate deficiency, chronic disease, or hemolysis; elevated hemoglobin (>16 g/dL) indicates polycythemia or dehydration; low WBC (<4.5K/µL) suggests immunosuppression or bone marrow disorders; elevated WBC (>11K/µL) indicates infection, inflammation, or leukemia; low platelets (<150K/µL) raise bleeding risk; elevated platelets (>400K/µL) suggest myeloproliferative disorders
    • Liver Function Test - Elevated bilirubin suggests hepatocellular injury, hemolysis, or biliary obstruction; elevated transaminases (AST/ALT >40 U/L) indicate hepatocyte necrosis from viral hepatitis, cirrhosis, or medication toxicity; elevated alkaline phosphatase suggests cholestasis or bone disease; low albumin (<3.5 g/dL) indicates hepatic synthetic dysfunction or protein malnutrition; elevated gamma GT confirms hepatobiliary involvement; reversed A/G ratio suggests cirrhosis or malignancy
    • Kidney Profile - Elevated creatinine (>1.2 mg/dL) and elevated BUN (>20 mg/dL) indicate reduced glomerular filtration rate (kidney disease); low eGFR (<60 mL/min/1.73m²) confirms chronic kidney disease; elevated uric acid (>6 mg/dL) predisposes to gout and renal stones; abnormal electrolytes (sodium, potassium, chloride) cause neurologic and cardiac dysfunction; elevated phosphorus with elevated creatinine suggests secondary hyperparathyroidism; high BUN/creatinine ratio suggests prerenal azotemia
    • Lipid Profile - Elevated total cholesterol (>200 mg/dL) increases cardiovascular risk; elevated LDL (>100 mg/dL) is primary atherosclerotic risk factor; low HDL (<50 mg/dL in women) removes cardioprotective effect; elevated triglycerides (>150 mg/dL) associated with VLDL increase and pancreatitis risk; elevated VLDL (>40 mg/dL) indicates increased cardiovascular risk; elevated ratios (cholesterol/HDL >5.0, LDL/HDL >3.0) worsen cardiovascular prognosis; high non-HDL cholesterol indicates atherogenic particle burden
    • Iron Studies - Low iron (<60 µg/dL) with high TIBC and low transferrin saturation (<20%) indicates iron deficiency anemia; elevated iron (>170 µg/dL) with elevated ferritin suggests hemochromatosis or secondary iron overload; low TIBC (<250 µg/dL) seen in chronic disease; high TIBC suggests iron deficiency; iron saturation >50% indicates iron overload
    • Thyroid Profile - Elevated TSH (>4.0 mIU/L) with low T4 indicates primary hypothyroidism; low TSH with elevated T3 and T4 suggests hyperthyroidism (Graves' disease or thyroiditis); isolated TSH elevation with normal free T4 indicates subclinical hypothyroidism; low TSH with normal free hormones indicates subclinical hyperthyroidism; normal pattern confirms euthyroid state
    • HbA1c - Values 5.7-6.4% indicate prediabetes; ≥6.5% confirms diabetes diagnosis; <5.7% indicates normal glucose control; HbA1c trending guides diabetes management efficacy; eAG >100 mg/dL correlates with inadequate glycemic control and increased microvascular/macrovascular complications
    • ESR - Values 20-40 mm/hr suggest acute inflammation or infection; >40 mm/hr indicates significant inflammatory/systemic disease (malignancy, autoimmune conditions, infection); elevations vary with age, anemia, and pregnancy; used for monitoring disease activity rather than diagnosis
    • hs-CRP - Values 3-10 mg/L indicate intermediate cardiovascular risk; >10 mg/L suggest high cardiovascular risk and significant inflammation; acute elevations (>100 mg/L) seen in acute infections or inflammation; persistent elevation suggests chronic inflammation (atherosclerosis, rheumatoid arthritis, inflammatory bowel disease)
    • Vitamin B12 - Values 200-400 pg/mL warrant careful monitoring as low-normal is associated with neurologic symptoms; <200 pg/mL indicates deficiency causing macrocytic anemia, peripheral neuropathy, and cognitive dysfunction; levels affected by pernicious anemia, vegan diet, gastrectomy, or metformin use
    • 25-OH Vitamin D - 20-29 ng/mL indicates insufficiency increasing osteoporosis and infection risk; <20 ng/mL indicates deficiency with increased risk of rickets, osteomalacia, falls, and immune dysfunction; levels >100 ng/mL may indicate toxicity with hypercalcemia
    • Urine Complete - Proteinuria (>trace) suggests glomerulonephritis or diabetic nephropathy; glucosuria indicates hyperglycemia or renal glycosuria; ketonuria seen in diabetes, starvation, or ketogenic diet; blood in urine (hematuria) suggests infection, stones, or malignancy; positive nitrites/leukocyte esterase indicate urinary tract infection; positive bilirubin suggests liver disease; abnormal specific gravity affects kidney concentrating ability; crystals may indicate stones or metabolic disorders
    • RF (Rheumatoid Factor) - Positive RF (>14 IU/mL) seen in rheumatoid arthritis, Sjögren's syndrome, and some infections; low-positive (15-60 IU/mL) may be seen in viral infections or other autoimmune conditions; high-positive (>60 IU/mL) strongly suggests rheumatoid arthritis; 20-30% of rheumatoid arthritis patients are seronegative; false positives occur in liver disease and hepatitis
    • Phosphorous - Low phosphorus (<2.5 mg/dL) causes muscle weakness, respiratory depression, and hemolysis; seen in hyperparathyroidism, diuretics, and malabsorption; high phosphorus (>4.5 mg/dL) occurs in kidney disease, hypoparathyroidism, and leads to secondary hyperparathyroidism and vascular calcification
    • Amylase - Elevated amylase (>110 U/L) indicates acute pancreatitis, chronic pancreatitis, salivary gland disease, or bowel perforation; very high levels (>1000 U/L) suggest acute pancreatitis; elevated amylase with normal lipase may indicate salivary gland or macroamylasemia; low amylase seen in advanced pancreatic disease or cirrhosis
    • Lipase - Elevated lipase (>60 U/L) is more specific for pancreatic disease than amylase; seen in acute and chronic pancreatitis, pancreatic cancer, and bowel perforation; remains elevated longer than amylase (up to 14 days); very high elevations (>3x normal) strongly suggest acute pancreatitis; may be elevated in advanced pancreatic cancer
    • Total IgE - Elevated IgE (100-1000 IU/mL) suggests allergic sensitization, atopy, or allergic asthma; very high IgE (>2000 IU/mL) indicates severe allergic disease, parasitic infections, or hyper-IgE syndrome; elevation helps guide immunotherapy decisions
    • CEA (Carcinoembryonic Antigen) - Values 2.5-5 ng/mL (non-smoker) or 5-10 ng/mL (smoker) warrant further investigation for malignancy; >10 ng/mL highly suspicious for cancer; particularly useful for monitoring colorectal, gastric, pancreatic, lung, and breast cancers; serial monitoring more useful than single value; can be falsely elevated in non-malignant conditions (liver disease, COPD, inflammatory bowel disease)
    • CA125 - Values 35-65 U/mL warrant evaluation for ovarian cancer or benign gynecologic pathology; >65 U/mL significantly raises concern for malignancy; markedly elevated (>500 U/mL) suggests advanced cancer; also elevated in endometriosis, fibroids, menstruation, pregnancy, and liver disease; serial monitoring tracks treatment response and recurrence; most useful in known ovarian cancer cases
    • CA15.3 - Values 25-50 U/mL suggest possible breast cancer or benign breast disease; >50 U/mL significantly suspicious for breast malignancy; markedly elevated (>200 U/mL) indicates advanced disease; also elevated in benign breast disease, endometriosis, ovarian cancer, and liver disease; primarily used to monitor treatment response and detect recurrence in known breast cancer; single elevated value requires clinical correlation
  • Associated Organs
    • Sugar (Glucose) Fasting - Pancreas (beta cells), Liver (glucose production), Muscles (glucose uptake); diagnoses diabetes mellitus, prediabetes, hypoglycemia; complications include diabetic ketoacidosis, hyperosmolar hyperglycemic state, microvascular disease (retinopathy, nephropathy, neuropathy), and macrovascular disease (CAD, stroke, PAD)
    • CBC - Bone Marrow (blood cell production), Spleen (RBC destruction), Blood vessels (circulation); diagnoses anemia, polycythemia, leukemia, lymphoma, infections, immune disorders; complications include hemorrhage (low platelets), infection (low WBC), and tissue hypoxia (low hemoglobin)
    • Liver Function Test - Liver (primary), Biliary system (ducts and gallbladder), Bone (alkaline phosphatase source); diagnoses hepatitis, cirrhosis, fatty liver disease, cholestasis, hemolysis, malignancy; complications include hepatic encephalopathy, ascites, variceal bleeding, coagulopathy, and metabolic derangements
    • Kidney Profile - Kidneys (glomerular filtration and tubular function), Heart (electrolyte effects), Bones (calcium-phosphorus metabolism); diagnoses acute/chronic kidney disease, electrolyte disturbances, gout, secondary hyperparathyroidism; complications include hypertension, anemia, bone disease, cardiovascular disease, uremia
    • Lipid Profile - Heart (atherosclerosis), Blood vessels (vascular disease), Liver (lipid metabolism), Pancreas (triglyceride-related pancreatitis); diagnoses dyslipidemia, metabolic syndrome; complications include coronary artery disease, myocardial infarction, stroke, peripheral artery disease, acute pancreatitis
    • Iron Studies - Bone Marrow (erythropoiesis), Liver (iron storage and metabolism), Gastrointestinal tract (iron absorption); diagnoses iron deficiency anemia, hemochromatosis, anemia of chronic disease; complications include fatigue, dyspnea, heart failure, cardiomyopathy, cirrhosis, arthropathy, hypogonadism
    • Thyroid Profile - Thyroid gland (hormone production), Pituitary (TSH secretion), Hypothalamus (TRH secretion); diagnoses hypothyroidism, hyperthyroidism, thyroiditis, subclinical thyroid disease; complications include arrhythmias, heart failure, myxedema coma, thyroid storm, infertility, depression
    • HbA1c/eAG - Pancreas (beta cell function), Red blood cells (glucose incorporation), Multiple organs (hyperglycemia effects); reflects 3-month average glucose control; diagnoses diabetes, prediabetes; predicts microvascular complications (retinopathy, nephropathy, neuropathy) and macrovascular disease
    • ESR - Systemic circulation, All tissues (inflammation response); nonspecific marker of systemic inflammation; elevated in infections, autoimmune diseases, malignancy, tissue necrosis; useful for disease monitoring rather than diagnosis
    • hs-CRP - Liver (acute phase response), Vascular endothelium (inflammation), All tissues (inflammatory response); predicts cardiovascular disease risk, reflects atherosclerotic burden; marker of systemic inflammation in infections, autoimmune disease, and metabolic syndrome
    • Vitamin B12 - Gastrointestinal tract (absorption), Liver (storage), Bone Marrow (erythropoiesis), Nervous system (myelin formation); deficiency causes macrocytic anemia, peripheral neuropathy, cognitive dysfunction, ataxia, paresthesias
    • 25-OH Vitamin D - Skin (synthesis), Liver and Kidney (metabolism), Bones (calcium absorption and remodeling), Immune system (lymphocyte function); deficiency causes rickets, osteomalacia, increased fracture risk, increased infection susceptibility, autoimmune disease predisposition
    • Urine Complete - Kidneys (filtration and reabsorption), Urinary tract (infection assessment), Pancreas (glucose control), Liver (bilirubin metabolism); detects kidney disease (proteinuria), urinary tract infection, diabetes, hemoglobinuria, myoglobinuria, biliary disease
    • RF - Joint synovium (autoimmune response), Immune system (autoantibody production), Multiple tissues (autoimmune attack); positive in rheumatoid arthritis causing joint destruction, systemic vasculitis, organ involvement; used to assess rheumatoid arthritis activity and treatment response
    • Phosphorous - Kidneys (reabsorption), Parathyroid glands (regulation), Bones (mineral composition), Cells (energy metabolism); abnormalities affect neuromuscular function, cardiac conduction, and bone structure
    • Amylase - Pancreas (exocrine function), Salivary glands, Small intestine; elevated in acute pancreatitis, chronic pancreatitis, salivary gland disorders, bowel perforation; complications of pancreatitis include organ failure, pseudocyst formation, necrosis
    • Lipase - Pancreas (primary source), Gastric mucosa; more specific for pancreatic disease than amylase; elevated in acute/chronic pancreatitis, pancreatic cancer, bowel perforation; complications include acute respiratory distress syndrome, multiple organ failure, shock
    • Total IgE - Immune system (allergic response), Mast cells (mediator release), All body tissues (allergic inflammation); elevated in allergic diseases causing anaphylaxis, angioedema, urticaria, asthma exacerbations; also elevated in parasitic infections and immunodeficiency
    • CEA - Gastrointestinal tract (primary malignancy site), Colon, Stomach, Pancreas, Lung, Breast; elevated in colorectal, gastric, pancreatic, lung, ovarian, and breast cancers; also elevated in benign conditions (smoking, COPD, inflammatory bowel disease, liver disease)
    • CA125 - Ovarian cancer (primary), Endometrial cancer, Peritoneal carcinoma, Breast, Lung; elevated in epithelial ovarian cancer causing ascites, peritoneal involvement, metastases; also elevated in benign gynecologic conditions and liver disease
    • CA15.3 - Breast cancer (primary), Ovarian cancer, Gastric cancer, Lung cancer; elevated in breast cancer indicating advanced disease, metastases, poor prognosis; monitors treatment response; also elevated in benign breast disease and other malignancies
  • Follow-up Tests
    • Sugar (Glucose) Fasting - If abnormal: Oral Glucose Tolerance Test (OGTT) for definitive diabetes diagnosis; Insulin level and C-peptide for insulin secretion assessment; Continuous glucose monitoring (CGM) for glucose fluctuation patterns; Repeat fasting glucose for confirmation; Additional testing if symptomatic hypoglycemia suspected
    • CBC - If abnormal: Peripheral blood smear for cell morphology; Bone marrow biopsy if severe cytopenias; Flow cytometry for hematologic malignancies; Ferritin and iron studies for anemia etiology; Reticulocyte count for bone marrow response; Coagulation studies if bleeding tendency; Repeat CBC in 1-2 weeks for trend assessment
    • Liver Function Test - If abnormal: Hepatitis A, B, C serology; Autoimmune hepatitis markers (ANA, anti-smooth muscle); Acetaminophen and alcohol levels if toxicity suspected; Ferritin and transferrin saturation for hemochromatosis; Liver ultrasound or CT for structural assessment; Prothrombin time/INR for synthetic function; Ammonia level if encephalopathy suspected; Repeat LFTs in 1-2 weeks for trend
    • Kidney Profile - If abnormal: Cystatin C for GFR confirmation; Urine protein-to-creatinine ratio (UPCR) or 24-hour urine protein for proteinuria quantification; Renal ultrasound for structural assessment; Renal artery Doppler if renovascular disease suspected; Electrophoresis if multiple myeloma suspected; Repeat renal panel in 1-2 weeks; ACE inhibitor initiation if diabetic proteinuria; Nephrology referral if eGFR <30 or rapid decline
    • Lipid Profile - If abnormal: Lipoprotein(a) [Lp(a)] measurement for genetic risk; Advanced lipid testing (apoB, particle size) if lifestyle modifications inadequate; Genetic testing for familial hypercholesterolemia if markedly elevated; Repeat lipid panel after 4-12 weeks of statin therapy; Cardiovascular risk assessment (CAC score, stress test); Consider ezetimibe, PCSK9 inhibitors, or bempedoic acid if statin-intolerant
    • Iron Studies - If abnormal: Ferritin level for iron stores (may need simultaneous ferritin measurement with initial panel); Hemoglobin electrophoresis if thalassemia suspected; Genetic testing for HFE mutations if hemochromatosis suspected; Liver biopsy for cirrhosis assessment if ferritin markedly elevated; GI evaluation for occult bleeding if iron deficiency; Repeat iron studies after iron supplementation (6-8 weeks); Colonoscopy if iron deficiency in adult without obvious source
    • Thyroid Profile - If abnormal: Free T3 and Free T4 (not total) for better assessment; Thyroid peroxidase (TPO) and thyroglobulin antibodies for autoimmune thyroiditis; TSI (TSH receptor antibodies) if Graves' disease suspected; Thyroid ultrasound for nodule assessment; Repeat TSH 4-6 weeks after levothyroxine initiation; I-131 uptake scan if hyperthyroidism etiology unclear; Endocrinology referral for thyroid cancer or treatment-resistant disease
    • HbA1c/eAG - If abnormal: Fasting glucose, OGTT, and random glucose for correlation; Insulin, C-peptide, and proinsulin levels; Continuous glucose monitoring (CGM) for glucose variability; Repeat HbA1c every 3 months until controlled, then every 6 months; Nephrology screening (UACR); Ophthalmology referral for retinal screening; Cardiology assessment for CAD risk; Annual renal function and lipid monitoring
    • ESR - If abnormal: Repeat ESR for confirmation; hs-CRP for inflammatory activity correlation; Infectious disease workup (blood cultures, imaging) if acute elevation; Autoimmune serologies (ANA, RF, anti-CCP); Age-appropriate malignancy screening; Temporal artery biopsy if ESR markedly elevated with constitutional symptoms; Repeat ESR in 2-4 weeks if chronic condition
    • hs-CRP - If elevated: Repeat hs-CRP for confirmation; Full lipid panel and glucose screening; Blood pressure and weight monitoring; Infectious disease evaluation if acute elevation; Autoimmune disease workup (ANA, ESR, RF); Statin therapy consideration for elevated cardiovascular risk; Lifestyle modification counseling (exercise, diet, smoking cessation); Repeat hs-CRP after 6-12 weeks
    • Vitamin B12 - If low-normal (<400 pg/mL) or abnormal: Methylmalonic acid (MMA) and homocysteine for functional deficiency assessment; Parietal cell and intrinsic factor antibodies for pernicious anemia; Schilling test (if available) for absorption assessment; Dietary history and GI pathology evaluation; Repeat B12 after supplementation (4-12 weeks); Monitor for neurologic complications; Consider prophylactic B12 in strict vegetarians and those with risk factors
    • 25-OH Vitamin D - If abnormal: PTH level for secondary hyperparathyroidism assessment; Calcium and phosphorus levels; Alkaline phosphatase (bone turnover marker); DEXA scan if low vitamin D with risk factors; Parathyroid imaging if PTH elevated; Repeat 25-OH vitamin D after 3 months of supplementation; Annual monitoring once on maintenance therapy; Bone health assessment in deficient patients
    • Urine Complete - If abnormal: 24-hour urine protein if proteinuria detected; Urine microscopy with culture and sensitivity if pyuria present; Urine electrolytes if electrolyte abnormalities on serum panel; Renal ultrasound if hematuria or recurrent infections; Repeat urinalysis after UTI treatment; Cystoscopy if persistent hematuria; Diabetes screening if glucosuria present
    • RF - If positive: Anti-CCP antibodies (more specific for RA); Joint imaging (X-rays, ultrasound, MRI) for structural damage; Complement levels (C3, C4) if lupus-like features; ANA, anti-Smith, anti-RNP for systemic lupus erythematosus; Rheumatology referral for diagnosis confirmation and treatment; Monitor with serial RF and CRP for disease activity; Consider disease-modifying antirheumatic drugs (DMARDs)
    • Phosphorous - If abnormal: PTH level for parathyroid function assessment; Vitamin D (25-OH) and calcium levels; Alkaline phosphatase; Renal function (creatinine, eGFR); Parathyroid imaging if PTH abnormal; ECG if severe electrolyte abnormality; Repeat phosphorous after treatment of underlying disorder; Monitor during phosphate binder therapy
    • Amylase - If elevated: Lipase (more specific for pancreas); Liver function tests to assess liver involvement; Calcium level if pancreatitis; Triglycerides assessment; Abdominal imaging (ultrasound, CT) for pancreatic structure; Repeat amylase and lipase if severe elevation; Alcohol history and cessation counseling; Follow-up amylase to document resolution
    • Lipase - If elevated: Amylase level for comparison; Liver function tests; Triglycerides, calcium, glucose screening; Abdominal ultrasound or CT for pancreatic pathology; Repeat lipase and amylase to document resolution; Endoscopic ultrasound (EUS) if recurrent pancreatitis; ERCP if biliary obstruction suspected; Alcohol cessation; Monitor for pancreatic insufficiency development
    • Total IgE - If elevated: Specific IgE testing for identified allergens; Eosinophil count; Pulmonary function testing if asthma suspected; Allergy skin testing for allergen identification; Parasitic serology if eosinophilia present; Immunoglobulin levels (IgA, IgG) if immunodeficiency suspected; Trial of antihistamines or allergy medications; Allergy specialist referral for severe disease
    • CEA - If elevated: Clinical correlation with risk factors and symptoms; Colonoscopy if not recently done (colorectal cancer screening); CT chest, abdomen, pelvis for malignancy staging if cancer suspected; Repeat CEA level in 1-2 weeks for trend; Baseline CEA if cancer diagnosed for monitoring; Consider gastroenterology or oncology referral; Serial CEA monitoring every 3 months if treated cancer
    • CA125 - If elevated: Transvaginal ultrasound for ovarian assessment; CT imaging (abdomen/pelvis) if malignancy suspected; Gynecology or gynecologic oncology referral; Repeat CA125 level in 1-2 weeks for trend; Pelvic exam; Rule out benign causes (menstruation, endometriosis); Baseline CA125 if ovarian cancer diagnosed; Serial monitoring every 3 months during treatment; Consider additional tumor markers (CA15.3, CEA)
    • CA15.3 - If elevated: Mammography and clinical breast examination; Breast ultrasound or MRI for imaging assessment; Oncology or breast specialist referral if malignancy suspected; Repeat CA15.3 in 1-2 weeks for trend; Biopsy if imaging abnormality detected; Baseline CA15.3 if breast cancer diagnosed; Serial monitoring every 3-6 months during/after treatment; Consider additional tumor markers (CEA, CA125); Rule out benign breast disease
  • Fasting Required?
    • YES - Fasting Required: 10-12 hours overnight fasting is mandatory for this comprehensive wellness package due to multiple metabolic tests requiring fasting baseline
    • Specific fasting duration: Minimum 10 hours, optimal 12 hours (such as 8 PM dinner, 8 AM blood draw) - Water intake is permitted during fasting period
    • Fasting impacts these specific tests: Glucose (must be fasting), Lipid Profile (triglycerides significantly affected), HbA1c (not affected but performed with fasting panel), Iron Studies (may be slightly affected), Liver Function Tests (marginally affected), Kidney Profile (not significantly affected but done with fasting), All other tests (not directly affected by fasting)
    • Medications to avoid before testing: Do NOT stop chronic medications without medical guidance; most medications can be taken with small sips of water; however, if taking medications affecting glucose or lipids, discuss timing with physician
    • Dietary restrictions: No food or beverages (except water) 10-12 hours before blood draw; no coffee (even black, as it stimulates gastric acid and may affect results); no artificial sweeteners; no vitamins or supplements unless prescribed
    • Preparation evening before: Light dinner 2-3 hours before bedtime; avoid alcohol 24 hours before testing; avoid excessive physical exercise evening before; ensure 6-8 hours sleep; avoid heavy smoking morning of test
    • Morning of test: No breakfast; no food or drinks except water; no smoking (within 30 minutes); no strenuous exercise; arrive early to rest 5-10 minutes before blood draw; wear loose clothing for easy blood draw access
    • Urine sample collection: First morning midstream urine is ideal for urine complete test; collect in sterile container provided by laboratory; if collection must be done at home, refrigerate sample if not delivered within 2 hours
    • Timing recommendations: Schedule test early morning between 7-9 AM for optimal results; avoid scheduling after strenuous activity; allow minimum 30 minutes rest before blood draw; inform phlebotomist of any fainting history
    • Special considerations: Women should schedule test at same time in menstrual cycle if tracking trends; inform technician of pregnancy or recent illness; note any medications for laboratory review; stress and anxiety can affect some results so remain calm; post-test meals may be consumed immediately after blood draw
    • Test scheduling: Results typically available within 24-48 hours; follow-up consultation recommended for result interpretation; repeat testing frequency: Annual for asymptomatic wellness, 3-6 months if abnormalities detected, as recommended by physician for chronic conditions

How our test process works!

customers
customers